Cue Biopharma Statistics
Total Valuation
Cue Biopharma has a market cap or net worth of $83.62 million. The enterprise value is $60.71 million.
Important Dates
The next estimated earnings date is Monday, March 10, 2025, after market close.
| Earnings Date | Mar 10, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Cue Biopharma has 63.35 million shares outstanding. The number of shares has increased by 13.18% in one year.
| Current Share Class | 63.35M |
| Shares Outstanding | 63.35M |
| Shares Change (YoY) | +13.18% |
| Shares Change (QoQ) | +2.10% |
| Owned by Insiders (%) | 0.55% |
| Owned by Institutions (%) | 20.32% |
| Float | 63.00M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.86 |
| Forward PS | 12.94 |
| PB Ratio | 3.13 |
| P/TBV Ratio | 3.30 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.37 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.22, with a Debt / Equity ratio of 0.37.
| Current Ratio | 2.22 |
| Quick Ratio | 2.12 |
| Debt / Equity | 0.37 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -39.69 |
Financial Efficiency
Return on equity (ROE) is -131.15% and return on invested capital (ROIC) is -60.74%.
| Return on Equity (ROE) | -131.15% |
| Return on Assets (ROA) | -50.18% |
| Return on Invested Capital (ROIC) | -60.74% |
| Return on Capital Employed (ROCE) | -162.88% |
| Revenue Per Employee | $179,849 |
| Profits Per Employee | -$841,736 |
| Employee Count | 53 |
| Asset Turnover | 0.17 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -36.54% in the last 52 weeks. The beta is 1.66, so Cue Biopharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.66 |
| 52-Week Price Change | -36.54% |
| 50-Day Moving Average | 1.27 |
| 200-Day Moving Average | 1.17 |
| Relative Strength Index (RSI) | 48.32 |
| Average Volume (20 Days) | 195,841 |
Short Selling Information
The latest short interest is 1.10 million, so 1.73% of the outstanding shares have been sold short.
| Short Interest | 1.10M |
| Short Previous Month | 1.08M |
| Short % of Shares Out | 1.73% |
| Short % of Float | 1.74% |
| Short Ratio (days to cover) | 2.65 |
Income Statement
In the last 12 months, Cue Biopharma had revenue of $9.53 million and -$44.61 million in losses. Loss per share was -$0.90.
| Revenue | 9.53M |
| Gross Profit | -27.76M |
| Operating Income | -45.64M |
| Pretax Income | -49.97M |
| Net Income | -44.61M |
| EBITDA | -45.23M |
| EBIT | -45.64M |
| Loss Per Share | -$0.90 |
Full Income StatementBalance Sheet
The company has $32.42 million in cash and $9.51 million in debt, giving a net cash position of $22.91 million or $0.36 per share.
| Cash & Cash Equivalents | 32.42M |
| Total Debt | 9.51M |
| Net Cash | 22.91M |
| Net Cash Per Share | $0.36 |
| Equity (Book Value) | 25.37M |
| Book Value Per Share | 0.42 |
| Working Capital | 20.47M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$38.26 million and capital expenditures -$64,000, giving a free cash flow of -$38.32 million.
| Operating Cash Flow | -38.26M |
| Capital Expenditures | -64,000 |
| Free Cash Flow | -38.32M |
| FCF Per Share | -$0.60 |
Full Cash Flow StatementMargins
| Gross Margin | -291.24% |
| Operating Margin | -478.80% |
| Pretax Margin | -468.02% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Cue Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.18% |
| Shareholder Yield | -13.18% |
| Earnings Yield | -53.35% |
| FCF Yield | -45.83% |
Analyst Forecast
The average price target for Cue Biopharma is $5.00, which is 278.79% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $5.00 |
| Price Target Difference | 278.79% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 23.56% |
| EPS Growth Forecast (5Y) | -12.58% |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Cue Biopharma has an Altman Z-Score of -10.46 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.46 |
| Piotroski F-Score | 4 |